|
| | Publication Year | Title | Author(s) |
| 21 | Mar-2020 | Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. | Gunjur, Ashray ; Chong, Geoffrey ; Lim, Adeline ; Lau, Eddie ; Mitchell, Paul L R ; John, Thomas ; Arulananda, Surein |
| 22 | Dec-2019 | RET-rearranged non-small-cell lung cancer and therapeutic implications. | Loh, Zoe ; Mitchell, Paul L R ; John, Thomas ; Arulananda, Surein |
| 23 | Sep-2019 | DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? | Arulananda, Surein; Mitchell, Paul L R ; John, Thomas |
| 24 | Aug-2019 | The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. | Mileshkin, Linda; Dunn, Catherine; Cross, Hannah; Duffy, Mary; Shaw, Mark; Antippa, Phillip; Mitchell, Paul L R ; Akhurst, Tim; Conron, Matthew; Moore, Melissa; Philip, Jenny; Bartlett, James; Emery, Jon; Zambello, Belinda |
| 25 | Apr-2019 | Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. | Rivalland, Gareth; Mitchell, Paul L R ; Murone, Carmel ; Asadi, Khashayer; Morey, Adrienne L; Starmans, Maud; Boutros, Paul C; Walkiewicz, Marzena; Solomon, Benjamin; Wright, Gavin; Knight, Simon; John, Thomas |
| 26 | Mar-2019 | Hospital lung surgery volume and patient outcomes. | Thai, Alesha A; Stuart, E; Te Marvelde, L; Milne, R L; Knight, S ; Whitfield, K; Mitchell, Paul L R |
| 27 | 4-Dec-2018 | Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. | Mileshkin, Linda; Dunn, Catherine; Cross, Hannah; Duffy, Mary; Shaw, Mark; Antippa, Phillip; Mitchell, Paul L R ; Akhurst, Tim; Conron, Matthew; Moore, Melissa; Philip, Jenny; Bartlett, James; Emery, Jon; Zambello, Belinda |
| 28 | Dec-2018 | Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. | Arulananda, Surein; Mitchell, Paul L R |
| 29 | Nov-2018 | The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. | Ren, Shengxiang; Tian, Qinrui; Amar, Nadav; Yu, Hui; Rivard, Christopher J; Caldwell, Charles; Ng, Terry L; Tu, Megan; Liu, Yiwei; Gao, Dexiang; Ellison, Kim; Suda, Kenichi; Rozeboom, Leslie; Rivalland, Gareth; Mitchell, Paul L R ; Zhou, Caicun; Hirsch, Fred R |
| 30 | 11-Oct-2018 | Correction to: Differences in cancer survival by sex: a population-based study using cancer registry data. | Afshar, Nina; English, Dallas R; Thursfield, Vicky; Mitchell, Paul L R ; Te Marvelde, Luc; Farrugia, Helen; Giles, Graham G; Milne, Roger L |
| 31 | 3-Oct-2018 | Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. | O'Keeffe, Linda M; Taylor, Gemma; Huxley, Rachel R; Mitchell, Paul L R ; Woodward, Mark; Peters, Sanne A E |
| 32 | 7-Sep-2018 | Differences in cancer survival by sex: a population-based study using cancer registry data. | Afshar, Nina; English, Dallas R; Thursfield, Vicky; Mitchell, Paul L R ; Te Marvelde, Luc; Farrugia, Helen; Giles, Graham G; Milne, Roger L |
| 33 | Aug-2018 | BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC? | Arulananda, Surein; Mitchell, Paul L R |
| 34 | 21-Jul-2018 | The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds. | Mazza, Danielle; Lin, Xiaoping; Walter, Fiona M; Young, Jane M; Barnes, David J; Mitchell, Paul L R ; Brijnath, Bianca; Martin, Andrew; Emery, Jon D |
| 35 | Dec-2017 | Lung cancer in Asian women and health system implications for Australia. | Emery, Jon David; Mitchell, Paul L R |
| 36 | Nov-2017 | Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. | Arulananda, Surein; Do, Hongdo; Musafer, Ashan; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 37 | Sep-2017 | Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase. | Do, Hongdo; Molania, Ramyar; Mitchell, Paul L R ; Vaiskunaite, Rita; Murdoch, John D; Dobrovic, Alexander |
| 38 | Sep-2017 | De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. | Thai, Alesha; Chia, Puey L; Russell, Prudence A; Do, Hongdo; Dobrovic, Alexander ; Mitchell, Paul L R ; John, Thomas |
| 39 | Aug-2017 | Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. | Tamjid, Babak ; Phan, Phuong L; John, Thomas ; Mitchell, Paul L R ; Gan, Hui K |
| 40 | Aug-2017 | Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context | Itchins, M; Chia, Puey Ling ; Hayes, SA; Howell, VM; Gill, AJ; Cooper, WA; John, Thomas ; Mitchell, Paul L R ; Millward, M; Clarke, SJ; Solomon, B; Pavlakis, N |
Loading...
2
0
20
0
false